Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases

Background: Patients with mantle cell lymphoma (MCL) have limited treatment options following covalent BTK inhibitor (cBTKi) therapy, with no standard regimens defined. The aim of this study was to investigate real-world treatment patterns and the outcomes for patients with MCL following cBTKi treatment utilizing two separate datasets - one from the US and one from Japan.